Biological
Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)
Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine) is a biological therapy with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_4
1
50%
Ph phase_3
1
50%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(2)
Detailed Status
Completed2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 31 (50.0%)
Phase 41 (50.0%)
Trials by Status
completed2100%
Recent Activity
0 active trials
Showing 2 of 2
completedphase_4
Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)
NCT00312858
completedphase_3
V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)
NCT00109343
Clinical Trials (2)
Showing 2 of 2 trials
NCT00312858Phase 4
Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)
NCT00109343Phase 3
V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)
All 2 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 2